Review Series 10.1172/JCI142246
1New Balance Foundation Obesity Prevention Center, Boston Children’s Hospital, and
2Division of Endocrinology, Boston Children’s Hospital, Boston, Massachusetts, USA.
3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
4Human Health, Resilience & Performance, Institute for Human and Machine Cognition, and
5Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.
Address correspondence to: Belinda S. Lennerz or David S. Ludwig, Boston Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Email: belinda.lennerz@childrens.harvard.edu (BSL). Email: david.ludwig@childrens.harvard.edu (DSL).
Find articles by Lennerz, B. in: JCI | PubMed | Google Scholar
1New Balance Foundation Obesity Prevention Center, Boston Children’s Hospital, and
2Division of Endocrinology, Boston Children’s Hospital, Boston, Massachusetts, USA.
3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
4Human Health, Resilience & Performance, Institute for Human and Machine Cognition, and
5Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.
Address correspondence to: Belinda S. Lennerz or David S. Ludwig, Boston Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Email: belinda.lennerz@childrens.harvard.edu (BSL). Email: david.ludwig@childrens.harvard.edu (DSL).
Find articles by Koutnik, A. in: JCI | PubMed | Google Scholar
1New Balance Foundation Obesity Prevention Center, Boston Children’s Hospital, and
2Division of Endocrinology, Boston Children’s Hospital, Boston, Massachusetts, USA.
3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
4Human Health, Resilience & Performance, Institute for Human and Machine Cognition, and
5Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.
Address correspondence to: Belinda S. Lennerz or David S. Ludwig, Boston Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Email: belinda.lennerz@childrens.harvard.edu (BSL). Email: david.ludwig@childrens.harvard.edu (DSL).
Find articles by
Azova, S.
in:
JCI
|
PubMed
|
Google Scholar
|
1New Balance Foundation Obesity Prevention Center, Boston Children’s Hospital, and
2Division of Endocrinology, Boston Children’s Hospital, Boston, Massachusetts, USA.
3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
4Human Health, Resilience & Performance, Institute for Human and Machine Cognition, and
5Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.
Address correspondence to: Belinda S. Lennerz or David S. Ludwig, Boston Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Email: belinda.lennerz@childrens.harvard.edu (BSL). Email: david.ludwig@childrens.harvard.edu (DSL).
Find articles by
Wolfsdorf, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1New Balance Foundation Obesity Prevention Center, Boston Children’s Hospital, and
2Division of Endocrinology, Boston Children’s Hospital, Boston, Massachusetts, USA.
3Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
4Human Health, Resilience & Performance, Institute for Human and Machine Cognition, and
5Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, USA.
Address correspondence to: Belinda S. Lennerz or David S. Ludwig, Boston Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. Email: belinda.lennerz@childrens.harvard.edu (BSL). Email: david.ludwig@childrens.harvard.edu (DSL).
Find articles by Ludwig, D. in: JCI | PubMed | Google Scholar
Published January 4, 2021 - More info
Carbohydrate restriction, used since the 1700s to prolong survival in people with diabetes, fell out of favor after the discovery of insulin. Despite costly pharmacological and technological developments in the last few decades, current therapies do not achieve optimal outcomes, and most people with diabetes remain at high risk for micro- and macrovascular complications. Recently, low-carbohydrate diets have regained popularity, with preliminary evidence of benefit for body weight, postprandial hyperglycemia, hyperinsulinemia, and other cardiometabolic risk factors in type 2 diabetes and, with more limited data, in type 1 diabetes. High-quality, long-term trials are needed to assess safety concerns and determine whether this old dietary approach might help people with diabetes attain clinical targets more effectively, and at a lower cost, than conventional treatment.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.